Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans: Lost in translation

British Journal of Pharmacology

Volumn 170, Issue 6, 2013, Pages 1273-1275

  Hysek, Cédric M ^a   Schmid, Yasmin ^a   Rickli, Anna ^a   Liechti, Matthias E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ADRENERGIC RECEPTOR; CARVEDILOL;

BODY TEMPERATURE MEASUREMENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; HEART STIMULATION; HUMAN; HYPERTHERMIA; LETTER; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; THERMOGENESIS;

ADRENERGIC ANTAGONISTS; BODY TEMPERATURE; CARBAZOLES; FEMALE; HEART RATE; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PROPANOLAMINES;

EID: 84886781120     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12398     Document Type: Letter

References (27)

1. Boehrer JD, Moliterno DJ, Willard JE, Hillis LD, Lange RA, (1993). Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 94: 608-610.
2. Brunt TM, Koeter MW, Niesink RJ, van den Brink W, (2012). Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology (Berl) 220: 751-762.
3. Dafters RI, (1995). Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav 58: 877-882.
4. Docherty JR, Green AR, (2010). The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol 160: 1029-1044.
5. Grunau BE, Wiens MO, Brubacher JR, (2010). Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM 12: 435-442.
6. Henry JA, Jeffreys KJ, Dawling S, (1992). Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet 340: 384-387.
7. Hysek CM, Liechti ME, (2012). Effects of MDMA alone and after pretreatement with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology (Berl) 224: 363-376.
8. Hysek CM, Vollenweider FX, Liechti ME, (2010). Effects of a β-blocker on the cardiovascular response to MDMA (ecstasy). Emerg Med J 27: 586-589.
9. Hysek CM, Schmid Y, Rickli A, Simmler LD, Donzelli M, Grouzmann E, et al. (2012a). Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol 166: 2277-2288.
10. Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Krähenbühl S, et al. (2012b). Duloxetine inhibits effects of MDMA ('ecstasy') in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS ONE 7: e36476.
11. Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME, (2013). α-Adrenergic receptors contribute to the acute effects of MDMA in humans. J Clin Psychopharmacol 33: 658-666.
12. Liechti ME, Gamma A, Vollenweider FX, (2001). Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154: 161-168.
13. Liechti ME, Kunz I, Kupferschmidt H, (2005). Acute medical problems due to Ecstasy use. Case-series of emergency department visits. Swiss Med Wkly 135: 652-657.
14. Martin TL, Chiasson DA, Kish SJ, (2007). Does hyperthyroidism increase risk of death due to the ingestion of ecstasy? J Forensic Sci 52: 951-953.
15. Mills EM, Banks ML, Sprague JE, Finkel T, (2003). Pharmacology: uncoupling the agony from ecstasy. Nature 426: 403-404.
16. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome I, Doblin R, (2010). The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25: 439-452.
17. Morefield KM, Keane M, Felgate P, White JM, Irvine RJ, (2011). Pill content, dose and resulting plasma concentrations of 3,4- methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users. Addiction 106: 1293-1300.
18. Oehen P, Traber R, Widmer V, Schnyder U, (2013). A randomized, controlled pilot study of MDMA (±3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol 27: 40-52.
19. Parrott AC, (2012). MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans. Drug Alcohol Depend 121: 1-9.
20. Ramoska E, Sacchetti AD, (1985). Propranolol-induced hypertension in treatment of cocaine intoxication. Ann Emerg Med 14: 1112-1113.
21. Rietjens SJ, Hondebrink L, Westerink RH, Meulenbelt J, (2012). Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions. Crit Rev Toxicol 42: 854-876.
22. Rogers G, Elston J, Garside R, Roome C, Taylor R, Younger P, et al. (2009). The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess 13: iii-iiv, ix-xii, 1-315.
23. Rusyniak DE, Banks ML, Mills EM, Sprague JE, (2004). Dantrolene use in 3,4-methylenedioxymethamphetamine (ecstasy)-mediated hyperthermia. Anesthesiology 101: 263-264.
24. Schutte JK, Schafer U, Becker S, Oldewurtel C, Starosse A, Singler P, et al. (2013). 3,4-Methylenedioxymethamphetamine induces a hyperthermic and hypermetabolic crisis in pigs with and without a genetic disposition for malignant hyperthermia. Eur J Anaesthesiol 30: 29-37.
25. Sprague JE, Moze P, Caden D, Rusyniak DE, Holmes C, Goldstein DS, et al. (2005). Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) in an animal model. Crit Care Med 33: 1311-1316.
26. Sprague JE, Yang X, Sommers J, Gilman TL, Mills EM, (2007). Roles of norepinephrine, free fatty acids, thyroid status, and skeletal muscle uncoupling protein 3 expression in sympathomimetic-induced thermogenesis. J Pharmacol Exp Ther 320: 274-280.
27. Williams H, Dratcu L, Taylor R, Roberts M, Oyefeso A, (1998). 'Saturday night fever': ecstasy related problems in a London accident and emergency department. J Accid Emerg Med 15: 322-326.